KÝR, Michal, Kristýna POLÁŠKOVÁ, Zuzana KUTTNEROVÁ, Tomáš MERTA, Jakub NERADIL, Jitka BERKOVCOVÁ, Ondřej HORKÝ, Marta JEŽOVÁ, Renata VESELSKÁ, Giannoula Lakka KLEMENT, Dalibor VALÍK and Jaroslav ŠTĚRBA. Individualization of Treatment Improves the Survival of Children With High-Risk Solid Tumors: Comparative Patient Series Analysis in a Real-Life Scenario. Online. Frontiers in Oncology. Lausanne: Frontiers Media S.A., 2019, vol. 9, JUL 17 2019, p. 1-11. ISSN 2234-943X. Available from: https://dx.doi.org/10.3389/fonc.2019.00644. [citováno 2024-04-23]
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Individualization of Treatment Improves the Survival of Children With High-Risk Solid Tumors: Comparative Patient Series Analysis in a Real-Life Scenario
Authors KÝR, Michal (203 Czech Republic, guarantor, belonging to the institution), Kristýna POLÁŠKOVÁ (203 Czech Republic, belonging to the institution), Zuzana KUTTNEROVÁ (703 Slovakia, belonging to the institution), Tomáš MERTA (203 Czech Republic, belonging to the institution), Jakub NERADIL (203 Czech Republic, belonging to the institution), Jitka BERKOVCOVÁ (203 Czech Republic), Ondřej HORKÝ (203 Czech Republic), Marta JEŽOVÁ (203 Czech Republic, belonging to the institution), Renata VESELSKÁ (203 Czech Republic, belonging to the institution), Giannoula Lakka KLEMENT (124 Canada), Dalibor VALÍK (203 Czech Republic) and Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution)
Edition Frontiers in Oncology, Lausanne, Frontiers Media S.A. 2019, 2234-943X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.848
RIV identification code RIV/00216224:14110/19:00108598
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3389/fonc.2019.00644
UT WoS 000475875500001
Keywords in English cancer; children; personalized medicine; targeted therapy; comparative effectiveness research; clinical trials; metronomic
Tags 14110230, 14110321, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 26/4/2021 12:55.
Abstract
Introduction: The individualization of treatment is attractive, especially in children with high-risk cancer. In such a rare and very heterogeneous group of diseases, large population-based clinical randomized trials are not feasible without international collaboration. We therefore propose comparative patient series analysis in a real-life scenario. Methods: Open cohort observational study, comparative analysis. Seventy patients with high-risk solid tumors diagnosed between 2003 and 2015 and in whom the treatment was individualized either empirically or based on biomarkers were analyzed. The heterogeneity of the cohort and repeated measurements were advantageously utilized to increase effective sample size using appropriate statistical tools. Results: We demonstrated a beneficial effect of empirically given low-dose metronomic chemotherapy (HR 0.46 for relapses, p = 0.017) as well as various repurposed or targeted agents (HR 0.15 for deaths, p = 0.004) in a real-life scenario. However, targeted agents given on the basis of limited biological information were not beneficial. Conclusions: Comparative patient series analysis provides institutional-level evidence for treatment individualization in high-risk pediatric malignancies. Our findings emphasize the need for a comprehensive, multi omics assessment of the tumor and the host as well whenever molecularly driven targeted therapies are being considered. Low-dose metronomic chemotherapy or local control of the disease may be a more rational option in situations where targeted treatment cannot be justified by robust evidence and comprehensive biological information. "Targeted drugs" may be given empirically with a realistic benefit expectation when based on robust rationale.
Links
LM2015090, research and development projectName: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/1586/2018, interní kód MUName: Personalizovaná léčba v dětské onkologii: na cestě k "liquid dynamic medecine" a "N-of-1 clinical trials" (Acronym: Personalizovaná léčba v dětské onkologii)
Investor: Masaryk University, Category A
NV16-33209A, research and development projectName: Sekvenování nové generace a expresní profilování jako diagnostický podklad pro návrhy individualizovaných léčebných plánů pro děti se solidními nádory
NV16-34083A, research and development projectName: Receptorové tyrozinkinázy a navazující signální dráhy jako potenciální cíle léčby refrakterních solidních nádorů dětského věku
90089, large research infrastructuresName: BBMRI-CZ II
PrintDisplayed: 23/4/2024 12:00